Maintenance of remission with low-dose olopatadine hydrochloride for itch in well- controlled chronic urticaria

Clinical, Cosmetic and Investigational Dermatology

Volumn 5, Issue , 2012, Pages 141-146

  Makino, Teruhiko ^a   Takegami, Yoshiaki ^a   Rehman, Mati Ur ^a   Yoshihisa, Yoko ^a   Ishida, Waka ^b   Toyomoto, Takashi ^c   Shimizu, Tadamichi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Niigata Central Hospital   (Japan)

^c Saiseikai Takaoka Hospital   (Japan)

Author keywords

Antihistamine; Chronic urticaria; Dose; Histamine; Itch; Olopatadine

Indexed keywords

OLOPATADINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC URTICARIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SKIN PRURITUS; VISUAL ANALOG SCALE;

EID: 84872858890     PISSN: 11787015     EISSN: None     Source Type: Journal    
DOI: 10.2147/CCID.S36812     Document Type: Article

References (23)

1. Morita K, Koga T, Moroi Y, Urabe K, Furue M. Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. J Dermatol. 2002;29:709-712.
2. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136:197-201.
3. Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004;64:2515-2536.
4. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol. 2003;3:363-368.
5. Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37:631-650.
6. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387-391.
7. Van der Vafk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre, Br J Dermatol. 2002;146:110-113.
8. Monroe E. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis. 2005;76:118-126.
9. Belsito DV. Second-generation antihistamines for the treatment of chronic idiopathic urticaria. J Drugs Dermatol. 2010;9:503-512.
10. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride: a new antiallergic drug. Jpn J Pharmacol. 2002;88:379-397.
11. Ohmori K, Hasegawa K, Tamura T, et al. Properties of olopatadine hydro- chloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54:809-829.
12. Takahashi H, Zhang Y, Morita E. Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis. Arch Dermatol Res. 2008;300:291-295.
13. Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal- and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol. 2004;29:526-532.
14. Okubo Y, Shigoka Y, Yamazaki M, Tsuboi R. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. J Dermatolog Treat. Epub August 24, 2011.
15. Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol. 2000;143:365-372.
16. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154:294-298.
17. Passalacqua G, Bousquet J, Bachert C, et al. The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy. 1996;51: 666-675.
18. Welch MJ, Meltzer EO, Simons FE. H1-antihistamines and the central nervous system. Clin Allergy Immunol. 2002;17:337-388.
19. Kamei H, Isaji A, Noda Y, et al. Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers. Arch Dermatol Res. 2012;304:263-272.
20. Kamei H, Noda Y, Ishikawa K, et al. Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers. Hum Psychopharmacol. 2003;18:611-618.
21. Enomoto T, Lu HQ, Yin M, et al. Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit. J Investig Allergol Clin Immunol. 2009;19:299-305.
22. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
23. Guest JF, Davie AM, Ruiz FJ, Greener MJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J. 2005;14:88-98.